Targeted therapies for cancer are increasingly being developed as an alternative for, and in addition to, immunotherapy. Altered tumor signaling can be exploited to single-out cancer cells for destruction while leaving normal cells intact. However, as we continue to learn, a therapeutic strategy that treats the biology of the tumor by itself in a vacuum without the context of the immune response and the surrounding microenvironment can lead to reduced efficacy. The new nCounter Tumor Signaling 360 gene expression panel homes in on signaling pathways involved in the sustained growth and maintenance of tumor cells while providing a holistic view of the immune response and microenvironment that can be complicit in the development and progression of cancer. Using the foundation of the PanCancer IO 360 and Breast Cancer 360 panels as a model, the Tumor Signaling 360 panel was designed to include 770 genes across 40+ pathways integral for tumor biology, immune evasion, and microenvironment remodeling. The panel offers the same direct, digital detection benefits of other NanoString gene expression panels and includes the 18-gene Tumor Inflammation Signature (TIS) as well as 14 immune cell type signatures for profiling the peripheral immune response.